Figure 3

Comparison of overall survival (OS) for resected pancreatic cancer patients between bi-weekly gemcitabine (GEM: Group A) and 5FU-based (5FU: Group B) in Stage 0–IIa. mo., months (Log-rank test P< 0.01).